On January 10, 2026, Swissmedic issued an announcement concerning the recall of designated batches of Esomeprazol MUT Sandoz gastro-resistant tablets. This action involves batches 239415, 239425, 239240, 239187, 239208, 239287, and 239283, which are being withdrawn to the level of retail distribution. The decision aims to safeguard public health and ensure the highest standards of product quality for healthcare providers and patients alike.
What changed?
Swissmedic has initiated a recall of specific batches of Esomeprazol MUT Sandoz gastro-resistant tablets. This recall targets batches 239415, 239425, 239240, 239187, 239208, 239287, and 239283. The recall action stems from quality-related concerns identified during routine surveillance activities. These findings necessitated an immediate control measure to prevent potential health risks associated with the affected products.
The recall applies to all distribution levels up to the retail stage. Healthcare professionals and retailers have been instructed to immediately withdraw the specified batches and cease their distribution to patients.
Who is affected?
The recall impacts healthcare providers, pharmacists, and patients who may have received or dispensed the specified batches of Esomeprazol MUT Sandoz tablets. Healthcare institutions relying on these tablets for therapeutic purposes are advised to verify their stock and ensure that no affected batches remain in circulation.
Patients who are currently using Esomeprazol MUT Sandoz are encouraged to consult their pharmacists or healthcare providers to determine if their supply is part of the affected batches. Any unused tablets from the specified recall should be returned promptly to the point of purchase.
Next steps and implications
Swissmedic has emphasized the importance of regulatory compliance and vigilance in ensuring the quality of medicinal products distributed across Switzerland. Manufacturers, distributors, and healthcare professionals are urged to collaborate in adhering to the recall process and to communicate effectively with all affected parties.
Consumers should be informed about the reasons underlying the recall and instructed on appropriate disposal or return processes. Additionally, healthcare providers should monitor for any adverse events that could be linked to the affected batches and report them promptly to Swissmedic through established channels.
This recall highlights the efficacy of post-market surveillance systems in identifying and mitigating risks, reinforcing Swissmedic’s commitment to ensuring patient safety.
FAQ
1. What are the affected batch numbers?
The impacted batches include 239415, 239425, 239240, 239187, 239208, 239287, and 239283.
2. Why are these batches being recalled?
The recall is due to quality-related issues identified during routine monitoring, which could pose risks to patients.
3. What should patients do if they have these products?
Patients should check their product batch numbers and return any affected tablets to the point of purchase or consult their healthcare provider.
4. Can patients continue using unaffected batches?
Yes, tablets from batches not included in the recall are safe to use when taken according to prescribed instructions.
Conclusion
Healthcare professionals and stakeholders in the pharmaceutical supply chain are expected to comply with Swissmedic’s recall instructions. Patients are urged to verify their current medications and seek professional guidance to ensure their safety. This recall underscores the critical role of post-market vigilance in upholding high industry standards.
Disclaimer
This article is for informational purposes only and does not constitute legal or regulatory advice. Always consult professional regulatory guidance for compliance matters.
Swissmedic Reference
For full information about the Swissmedic announcement, see the link below.
https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/qualitaetsmaengel-und-chargenrueckrufe/batch-recalls/chargenrueckruf-esomeprazol-mut-sandoz-magensaftresistente-tabl.html